205 related articles for article (PubMed ID: 32121654)
1. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.
Mackowiak da Fonseca J; Mackowiak da Fonseca II; Nagamine MK; Massoco CO; Nishiya AT; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987941
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
6. Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study.
da Fonseca IIM; Nagamine MK; Gentile LB; Nishiya AT; da Fonseca JM; de Oliveira Massoco C; Ward JM; Liu S; Leppla SH; Dagli MLZ
Vet Res Commun; 2024 May; ():. PubMed ID: 38805149
[TBL] [Abstract][Full Text] [Related]
7. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis of canine oral malignant melanoma metastasis-associated gene expression.
Bowlt Blacklock KL; Birand Z; Selmic LE; Nelissen P; Murphy S; Blackwood L; Bass J; McKay J; Fox R; Beaver S; Starkey M
Sci Rep; 2019 Apr; 9(1):6511. PubMed ID: 31019223
[TBL] [Abstract][Full Text] [Related]
9. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
10. Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors.
Nakaichi M; Yunuki T; Okuda M; Une S; Taura Y
Res Vet Sci; 2007 Apr; 82(2):271-9. PubMed ID: 17011604
[TBL] [Abstract][Full Text] [Related]
11. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
Docampo MJ; Cabrera J; Rabanal RM; Bassols A
Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Rønø B; Rømer J; Liu S; Bugge TH; Leppla SH; Kristjansen PE
Mol Cancer Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16432166
[TBL] [Abstract][Full Text] [Related]
14. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Liu S; Bugge TH; Leppla SH
J Biol Chem; 2001 May; 276(21):17976-84. PubMed ID: 11278833
[TBL] [Abstract][Full Text] [Related]
15. Production of recombinant lethal factor of
Gholami M; Moghbeli M; Kafilzadeh F; Kargar M; Torbati MB; Tavizi A; Bellevile S; Hatami J; Eslami Z
Prep Biochem Biotechnol; 2021; 51(1):9-15. PubMed ID: 32393098
[TBL] [Abstract][Full Text] [Related]
16. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision.
Dank G; Rassnick KM; Sokolovsky Y; Garrett LD; Post GS; Kitchell BE; Sellon RK; Kleiter M; Northrup N; Segev G
Vet Comp Oncol; 2014 Mar; 12(1):78-84. PubMed ID: 22737988
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas.
Silveira TL; Veloso ES; Gonçalves INN; Costa RF; Rodrigues MA; Cassali GD; Del Puerto HL; Pang LY; Argyle DJ; Ferreira E
Vet Comp Oncol; 2020 Dec; 18(4):727-738. PubMed ID: 32323423
[TBL] [Abstract][Full Text] [Related]
18. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Schafer JM; Peters DE; Morley T; Liu S; Molinolo AA; Leppla SH; Bugge TH
PLoS One; 2011; 6(5):e20532. PubMed ID: 21655226
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Boria PA; Murry DJ; Bennett PF; Glickman NW; Snyder PW; Merkel BL; Schlittler DL; Mutsaers AJ; Thomas RM; Knapp DW
J Am Vet Med Assoc; 2004 Feb; 224(3):388-94. PubMed ID: 14765798
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.
Ottnod JM; Smedley RC; Walshaw R; Hauptman JG; Kiupel M; Obradovich JE
Vet Comp Oncol; 2013 Sep; 11(3):219-29. PubMed ID: 23909996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
